CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug

Phase 3Positive
AI Analysis

Summary

Kallyope rebrands as TriGemX Bio and secures $94M in funding to advance Phase 3 trials of a migraine drug acquired from Tanabe Pharma, following a restructuring after its Novo obesity partnership.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.60
rebrandPhase 3migrainefundingrestructuring

Read the original article

Published by Endpoints News on October 1, 2026 11:00 AM

Read Original